VIDEO: Identifying Risk Factors for Post-Stroke Epilepsy
Beate Diehl, MD, PhD, FRCP, discusses her research on post-stroke epilepsy.
AES 2016 Coverage
VIDEO: Gap in Provider Knowledge Delays Diagnosis, Treatment of Infantile Spasms
Shaun Hussain, MD, MS, discusses a gap in health care provider knowledge that may contribute to the delay in the diagnosis and treatment of infantile spasms.
VIDEO: Elizabeth Thiele, MD, PhD Discusses Latest Cannabidiol Research
Elizabeth Thiele, MD, PhD discusses results from her research on cannabidiol in Lennox-Gastaut syndrome.
Significant Drug-Drug Interactions With Cannabidiol and Antiepileptics
Clobazam had been previously identified as an AED with a significant interaction with CBD.
VIDEO — Industry Update: Justin Gover, CEO, GW Pharmaceuticals on Epidiolex Status
Justin Gover, CEO of GW Pharmaceuticals, the parent company of Greenwich Biosciences, discusses the status of the company’s cannabidiol product Epidiolex on the heels of positive results from several placebo-controlled trials in epileptic syndromes.
Social Support a Significant Factor in Development of Anxiety, Depression in Epilepsy
Number of AEDs and seizure frequency also influenced depression in people with epilepsy.
Accurate Surgical Localization Using Combined Imaging Approach in Epilepsy
Concordant EEG/fMRI and ESI predicted outcomes with 100% sensitivity and specificity.
Factors Predictive of Everolimus Efficacy in Tuberous Sclerosis Complex
Adjunctive everolimus treatment has been found to significantly reduce frequency of treatment-resistant seizures in TSC.
A Novel Risk Score for Seizures After Stroke
The triple-validated SeLECT score may help identify patients suited for antiepileptic drug trials.
Cannabidiol Reduces Seizure Frequency in Refractory Dravet Syndrome
Results of the phase 3, placebo-controlled trial support previous findings from an expanded-access program.
-
Loading...
-
Loading...
Want to read more?
Please login or register first to view this content.
Next post in AES 2016 Coverage
